Categories: News

Awakn Life Sciences to Participate at Upcoming December Conferences

Toronto, Ontario–(Newsfile Corp. – December 3, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, is scheduled to present at the following upcoming virtual December investor conferences.

H.C. Wainwright 2nd Annual Psychedelics Conference
Presentation: On Demand Beginning Monday, December 6th at 7:00 a.m. ET
Registration: Click here

Stifel GMP 2nd Annual The Future of Healthcare Conference
Presentation: Wednesday, December 8th at 2:00 p.m. ET
Registration: Click here

For more information about each conference, or to schedule a one-on-one meeting with Awakn’s management team, please contact your Stifel representative, H.C. Wainwright representative or KCSA Strategic Communications at Awakn@kcsa.com.

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will deliver these evidence backed psychedelic therapies in clinics in the UK and Europe and through licensing partnerships globally.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
Adonohoe@KCSA.com

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
Awakn@roadcommunications.co.uk

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106319

Staff

Recent Posts

Congress Passes Bills Making Major Investments in Alzheimer’s

Bill Increases Funding for Alzheimer’s Research and Prevention EffortsWASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) --…

23 hours ago

Back Pain, Prostatitis, Enlarged Prostate (BPH) and Kidney Stones are Treated with the Safest Thermobalancing Therapy

The first safe therapy with Dr Allen's Device has once again proved its ability to…

2 days ago

Defence Completes 2nd Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…

3 days ago

Masimo Corporation Board of Directors Authorizes Management to Evaluate the Separation of Consumer Business

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products,…

3 days ago

Axonics Stockholders Approve Merger Agreement with Boston Scientific

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt…

3 days ago

Pramana Achieves Industry-Leading Milestone with Digital Pathology 2.0 Technology

Over 6.5 Million Glass Slides Digitized in the Last 12 Months and 15 Billion Images…

3 days ago